Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-05-14

Development of mineral bone substitute injectable by percutaneous a pproach and the minimally invasive catheterization technique

Objective



The elaboration of synthetic material compatible with the bones and tissues of the human body has contributed to the development of new therapeutic methodologies to treat the bone lesions. The PMMA (Polymethylmethracrylite) cement has been used for many years as a filling material for joint implants and more recently for vertebroplasties. Despite its good adhesion and mechanical properties, this acrylic cement presents some drawbacks like side effects and the necrosis of the surrounding tissues resulting from the exothermic reaction developed during the application. Today the tendency is towards the development of bioresorbable and osteoconductor bone substitutes like HAP (hydroxyapatite) which over comes these problems and optimises the bone in growth in the lesion area. Up to now, HAP had been used mainly as a coating material for implants. It has been recently introduced in orthopaedics to treat bone lesions and consolidate bone fractures (pseudarthrosis) in situ.

The product available to the practitioner is a calcium phosphate powder which in presence of water constitutes a paste which will harden and become an HAP in situ. Up to now the consistency of the material has limited its application to the hand packing of lesion in open surgical sites. The objective of the project is to develop a mineral bone substitute inject able by percutaneous approach and capable to fill voids, hollows and areas deficient of bone tissue even in the most distal or less directly reachable places. The new developments will allow the injection through long (40 cm) and narrow (2 mm) catheters. More, the new bone substitute will be inject able in biologic liquid without delitment. A minimal invasive catheterisation technique will be developed to reach the metaphysis and epiphysis lesions or tumour in the long bones from a safe entry point in the diaphysis cortical to avoid open site surgery and direct penetration of the articulation joint.

This new operation technique is expected to reduce very significantly (about 70 %) the medical costs for the foreseen treatments, improve the patient comfort (from a 3 weeks hospital journey to 3 days) and reduce mortality. The SME partners gather the necessary competences to manufacture both the bone substitute and the catheterisation equipment. Starting from the existing technologies, the RTD performers will develop the inject able product and the catheterisation technique. The biomaterial and catheterisation equipment will be developed and tested in vitro on anatomic pieces. The final bone substitute formulation and equipment prototypes will then be validated in vivo on rabbits and sheep. At the end of the project the clinical validation of the new technology on the human will start.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

Data not available

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

CRS - Cooperative research contracts

Coordinator

TEKNIMED S.A.
EU contribution
No data
Address
8,Rue du Corps Franc-Pommiès 8
65502 VIC EN BIGORRE
France

See on map

Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (4)

My booklet 0 0